Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Andrew Finnerty"'
Autor:
Joan C. Fitzgerald, Niamh Duffy, Giacomo Cattaruzzi, Francesco Vitrani, Alice Paulitti, Flavia Mazzarol, Prisca Mauro, Antonio Sfiligoj, Francesco Curcio, Deirdre M. Jones, Veronica McInerney, Janusz Krawczyk, Jack Kelly, Andrew Finnerty, Katya McDonagh, Una McCabe, Matthew Duggan, Lauren Connolly, Georgina Shaw, Mary Murphy, Frank Barry
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
In recent years mesenchymal stromal cells (MSCs) have received a great deal of interest for the treatment of major diseases, but clinical translation and market authorization have been slow. This has been due in part to a lack of standardization in c
Externí odkaz:
https://doaj.org/article/7945c89fae8f404c8b04f0e9d61db25e
Autor:
Sara Azhari Mohamed, Aoife Duffy, Veronica McInerney, Janusz Krawczyk, Amjad Hayat, Sean Naughton, Andrew Finnerty, Miriam Holohan, Aaron Liew, Muhammad Tubassam, Stewart Redmond Walsh, Timothy O'Brien, Linda Howard
Publikováno v:
Cytotherapy. 24:1259-1267
Approximately 1 in 3 patients with critical limb ischemia (CLI) are not suitable for surgical or endovascular revascularization. Those "no-option" patients are at high risk of amputation and death. Autologous bone marrow mesenchymal stromal cells (MS
Autor:
Veronica McInerney, Miriam Holohan, Sara Mohamed, Muhammad Tubassam, Tony Moloney, Sean Naughton, Amjad Hayat, Aaron Liew, Stewart R. Walsh, Janusz Krawczyk, Aoife Duffy, Andrew Finnerty, Linda Howard, Paul E. Burke, Eamon G. Kavanagh, Timothy O'Brien
Publikováno v:
Cytotherapy. 22(6)
Background Critical limb ischemia (CLI) is the most severe manifestation of peripheral vascular disease. Revascularization is the preferred therapy, but it is not achievable in 25%–40% of patients due to diffuse anatomic distribution of the disease